“Made to order” needs a reason.

What compounding means

When medicine is made or mixed for an order, that is called compounding. This can be done by a pharmacist or doctor, or by a medicine-making site with Food and Drug Administration (FDA) registration.

The September 26, 2026 record showed that compounded drugs were not FDA-approved.

FDA does not assess the quality, safety, or effectiveness of these drugs before they are marketed.

Sometimes compounding can address a medical need that an approved medicine leaves unmet.

Why the old shortage claim is not enough

December 19, 2024 was the date FDA confirmed resolution of the shortage of tirzepatide injections.

After the shortage ended, FDA gave medicine makers time to stop relying on the shortage as a reason for making copies. That time ended on February 18, 2025 for regular compounding pharmacies. For the larger sites known as outsourcing facilities, March 19, 2025 marked the end of that time.

Outsourcing facilities register with FDA and make batches of medicine without needing a prescription for each person.

The September 26, 2026 check found no tirzepatide entry on FDA’s shortage list.

If your local pharmacy has run out, that alone does not establish a nationally listed shortage.

Ask what would change for you

Under the rules checked September 26, 2026, the law limits how often a pharmacy can copy a drug already on the market.

For a regular compounding pharmacy, the person writing the prescription must decide whether a change matters enough for that particular patient.

Charging less, by itself, cannot satisfy that requirement for a difference.

For example, compounding may meet the needs of someone allergic to a dye in an approved medicine.

That is a general example, not a reason to assume tirzepatide needs changing for you. Ask what ingredient or other feature would change, and what medical need that change would meet.

Check the approval claim